Table 1 Lifetime costs and effects of HPV vaccination in Burkina Faso (2022–2031) assuming no cross-protection
From: Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study
No vaccine | CECOLIN | GARDASIL-4 | CERVARIX | GARDASIL-9 | |
|---|---|---|---|---|---|
Lifetime costs and effects | |||||
Cervical cancer cases (local) | 25,684 | 16,080 | 16,176 | 16,138 | 7,308 |
Cervical cancer cases (regional) | 14,517 | 9,089 | 9,143 | 9,121 | 4,130 |
Cervical cancer cases (distant) | 21,776 | 13,633 | 13,715 | 13,682 | 6,196 |
Cervical cancer cases with treatment | 61,976 | 38,802 | 39,034 | 38,941 | 17,634 |
Cervical cancer deaths | 51,515 | 32,253 | 32,446 | 32,369 | 14,658 |
DALYs (discounted*) | 221,841 | 139,162 | 139,989 | 139,658 | 63,640 |
Vaccine program costs (discounted*) | US$ 0 | US$ 24,501,708 | US$ 34,663,269 | US$ 36,953,148 | US$ 164,858,263 |
Societal healthcare costs (discounted*) | US$ 12,044,932 | US$ 7,556,478 | US$ 7,601,375 | US$ 7,583,416 | US$ 3,456,536 |
Differences (comparator = no vaccine) | |||||
Cervical cancer cases (local) | - | 9,604 | 9,508 | 9,546 | 18,376 |
Cervical cancer cases (regional) | - | 5,428 | 5,374 | 5,396 | 10,387 |
Cervical cancer cases (distant) | - | 8,143 | 8,061 | 8,094 | 15,580 |
Cervical cancer cases with treatment | - | 23,174 | 22,942 | 23,035 | 44,342 |
Cervical cancer deaths | - | 19,262 | 19,069 | 19,146 | 36,857 |
DALYs (discounted*) | - | 82,679 | 81,852 | 82,183 | 158,201 |
Vaccine program costs (discounted*) | - | US$ 24,501,708 | US$ 34,663,269 | US$ 36,953,148 | US$ 164,858,263 |
Societal healthcare costs (discounted*) | - | -US$ 4,488,454 | -US$ 4,443,557 | -US$ 4,461,516 | -US$ 8,588,396 |
Cost (US$) per DALY averted (comparator = no vaccine) | |||||
Societal cost perspective | - | ||||
Cost (discounted*) | - | US$ 20,013,254 | US$ 30,219,712 | US$ 32,509,591 | US$ 156,269,867 |
DALYs averted (discounted*) | - | 82,679 | 81,852 | 82,183 | 158,201 |
Cost per DALY averted (discounted*) | - | US$ 242 | Dominated* | Dominated* | US$ 988 |
Cost (US$) per DALY averted (comparator = next least costly non-dominated** option) | |||||
Societal cost perspective | - | ||||
Cost (discounted*) | - | US$ 20,013,254 | Dominated** | Dominated** | US$ 136,256,613 |
DALYs averted (discounted*) | - | 82,679 | Dominated** | Dominated** | 75,522 |
Cost per DALY averted (discounted*) | - | US$ 242 | Dominated** | Dominated** | US$ 1,804 |